Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematolog… (NCT06415968) | Clinical Trial Compass
TerminatedNot Applicable
Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations
Stopped: difficulty of inclusion, PI decision
France138 participantsStarted 2024-09-10
Plain-language summary
Intimate violence against individuals, which is particularly marked among women, is one of the most widespread human rights violations in the world.
The Women Abuse Screening Tool (WAST) self-questionnaire is a screening tool validated in French.
Our preliminary data describing the association between intimate violence against women and the first attack of unexplained venous thromboembolic disease, show a significant frequency of positive responses to the WAST among women attending a biological hematology consultation at the CHU de Nîmes, for reasons of hemostasis disorders (8% out of the first 200 cases).
The study authors wish to establish the prevalence of this situation among patients presenting to the CHU de Nîmes for hematological exploration and management. They hypothesize that the prevalence of violence against individuals seen in Hematology consultations is higher among individuals with hemostasis pathologies (hemorrhagic and thrombotic pathologies) than those with cellular pathologies, and higher among women than men.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Currently in a relationship or has been in one in the last 12 months, regardless of the length of the relationship
* Willing to complete the anonymous WAST self-questionnaire
* able to read and understand French
* Outpatient consultant at Nîmes University Hospital in one of the following departments:
* Biological hematology consultation
* Clinical hematology consultation
* Vascular medicine consultation
Exclusion Criteria:
* Individuals under court protection, guardianship or curatorship
* Individuals unable to read and understand French
* Individuals who have already completed the WAST questionnaire during the study period
* Individuals unable to get away from their partner during the consultation to complete the questionnaire in isolation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prevalence of patients experiencing Intimate Partner Violence according to consulting department